An interventional study of Subcutaneous tissue release with the Cabochon System in Gynoid Lipodystrophy, sponsored by Merz North America, Inc.. Completed at 3 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-10.
Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Lipodystrophy with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Lipodystrophy · United States.
Among the 77 studies in Lipodystrophy with a site in United States, this one is the 21st largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2012, is one of 15 with no phase, and was the 53rd registered.
140 studies on the registry are indexed under Lipodystrophy; 11 are open to participants now.
Browse Lipodystrophy studies →5 of the 77 studies in Lipodystrophy with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–65
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 6 mo–98 yrs
University of Michigan · Sites in United States, Brazil, Turkey
Chiesi Farmaceutici S.p.A. · Sites in United States, France, Germany and 2 more countries
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Lipodystrophy studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 18 · Phase 3 7 · Phase 4 10
First in 1999; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 46 across 97 interventional studies indexed under Lipodystrophy.
Median enrollment 44 across the 51 interventional studies, 86 across the 22 observational. Of the 66 that completed or were terminated, 33 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz North America, Inc., one of the names counted as Merz Pharma. Under that name alone:
Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.
Merz Pharma has 1 study filed under Lipodystrophy — fewer than ten, so there is no comparison to draw.
3 of the studies in Lipodystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT05996536National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD) | 2027-06-01 |
| NCT02262806National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 77 studies in Lipodystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the Cabochon System for the improvement in the appearance of cellulite.
Inclusion Criteria:
Exclusion Criteria:
taken within 14 days of treatment:
For Extended Follow-Up the following apply:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Subcutaneous tissue release with the Cabochon System
Device: Subcutaneous tissue release with the Cabochon System
Device: Subcutaneous tissue release
Also known as: Cellfina®
Mean Change (Decrease) in Cellulite Severity
Achievement of ≥1 point mean reduction in the 0-5 point Cellulite Severity Scale as determined by independent physician assessment of subject photographs taken before and 3 and 5 years after treatment. Cellulite severity was graded on a 0 (no cellulite) to 5 (severe cellulite) for each subject photograph taken at baseline (before treatment) and 3 and 5 years after treatment by an independent and blinded physician panel. The primary endpoint was achievement of a mean post-treatment severity at 3 and 5 years for the study population which was a minimum of 1 point lower than the baseline severity.
Time frame: Treatment to 3 and 5 years
Improvement in Cellulite Severity Grade
Percentage of subjects which were scored to have improvement of one grade or more in a 4 point Severity Grade (none, mild, moderate, severe) as determined by independent blinded physician assessment of subject photographs taken before and 3 and 5 years after treatment.
Time frame: 3 and 5 years
Improved Appearance
Improvement in subject's cellulite appearance according to a Global Aesthetic Improvement Scale (GAIS) evaluated by independent and blinded physician panel assessment of subject photographs taken before and 3 and 5 years after treatment. Change in the cellulite severity was rated according to 5 measures: * Very much improved: Optimal cosmetic result in the treated areas for this subject * Much improved: Marked or significant improvement in appearance of the treated areas from the initial condition * Improved: Noticeable improvement in appearance of the treated areas from the initial condition but more subtle in magnitude * No Change: The appearance of the treated areas is essentially the same as the original condition * Worse: The appearance of the treated areas is worse than the original condition
Time frame: Treatment to 3 and 5 years
Subject Satisfaction
Subject rated satisfaction according to a 5 point Likert scale after treatment: Very Satisfied Satisfied Neutral Unsatisfied Very Unsatisfied
Time frame: Treatment to 3 and 5 years
Procedure Tolerability
Subject rated pain according to a 0-10 numerical rating scale. Pain scale ranges from 0 (no pain) to 10 (worst possible pain). Measure was reported as mean and standard deviation of the pain score
Time frame: Treatment to 3 and 5 years
Safe Treatment
Freedom from serious adverse events directly attributable to the Cabochon System or procedure.
Time frame: Treatment to 3 and 5 years
| Milestone | Subcutaneous Tissue Release |
|---|---|
| Started | 55 |
| 3-year follow-up | 45 |
| 5-year follow-up | 37 |
| Completed | 37 |
| Not completed | 18 |
Achievement of ≥1 point mean reduction in the 0-5 point Cellulite Severity Scale as determined by independent physician assessment of subject photographs taken before and 3 and 5 years after treatment. Cellulite severity was graded on a 0 (no cellulite) to 5 (severe cellulite) for each subject photograph taken at baseline (before treatment) and 3 and 5 years after treatment by an independent and blinded physician panel. The primary endpoint was achievement of a mean post-treatment severity at 3 and 5 years for the study population which was a minimum of 1 point lower than the baseline severity.
| units on a scale | Subcutaneous Tissue Release |
|---|---|
| 3 years | 2.0 (1.7 to 2.3) |
| 5 years | 1.8 (1.4 to 2.2) |
Percentage of subjects which were scored to have improvement of one grade or more in a 4 point Severity Grade (none, mild, moderate, severe) as determined by independent blinded physician assessment of subject photographs taken before and 3 and 5 years after treatment.
| percentage of subjects | Subcutaneous Tissue Release |
|---|---|
| 3 years | 91.1 (79.3 to 100) |
| 5 years | 86 (75 to 100) |
Improvement in subject's cellulite appearance according to a Global Aesthetic Improvement Scale (GAIS) evaluated by independent and blinded physician panel assessment of subject photographs taken before and 3 and 5 years after treatment. Change in the cellulite severity was rated according to 5 measures: * Very much improved: Optimal cosmetic result in the treated areas for this subject * Much improved: Marked or significant improvement in appearance of the treated areas from the initial condition * Improved: Noticeable improvement in appearance of the treated areas from the initial condition but more subtle in magnitude * No Change: The appearance of the treated areas is essentially the same as the original condition * Worse: The appearance of the treated areas is worse than the original condition
| percentage of subjects | Subcutaneous Tissue Release - 3 Years | Subcutaneous Tissue Release - 5 Years |
|---|---|---|
| Very Much Improved | 8.9 (2.5 to 21.2) | 5.4 (0.7 to 18.2) |
| Much Improved | 46.7 (31.7 to 62.1) | 29.7 (15.9 to 47.0) |
| Improved | 44.4 (29.6 to 60) | 64.9 (47.5 to 79.8) |
| No Change | 0 (0 to 6.9) | 0 (0 to 9.5) |
| Worse | 0 (0 to 6.9) | 0 (0 to 9.5) |
Subject rated satisfaction according to a 5 point Likert scale after treatment: Very Satisfied Satisfied Neutral Unsatisfied Very Unsatisfied
| percentage of subjects | Subcutaneous Tissue Release - 3 Years | Subcutaneous Tissue Release - 5 Years |
|---|---|---|
| % Very Satisfied | 42.2 (27.7 to 57.9) | 46.0 (29.5 to 63.1) |
| % Satisfied | 51.1 (35.8 to 66.3) | 32.4 (18.0 to 49.8) |
| % Neutral | 6.7 (1.4 to 18.3) | 18.9 (8.0 to 35.2) |
| % Unsatisfied | 0 (0 to 6.8) | 0 (0 to 9.5) |
| % Very Unsatisfied | 0 (0 to 6.8) | 0 (0 to 9.5) |
Subject rated pain according to a 0-10 numerical rating scale. Pain scale ranges from 0 (no pain) to 10 (worst possible pain). Measure was reported as mean and standard deviation of the pain score
| units on scale | Subcutaneous Tissue Release - 3 Years | Subcutaneous Tissue Release - 5 Years |
|---|---|---|
| Procedure Tolerability | 0 ± 0 | 0 ± 0 |
Freedom from serious adverse events directly attributable to the Cabochon System or procedure.
| occurence of serious adverse events | Subcutaneous Tissue Release - 3 Years | Subcutaneous Tissue Release - 5 Years |
|---|---|---|
| Safe Treatment | 0 | 0 |
Collected over From baseline up to year 5.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous Tissue Release - 3 Years | 0/55 (0%) | 0/55 (0%) | 4/55 (7.3%) |
| Subcutaneous Tissue Release - Years 4-5 | 0/37 (0%) | 0/37 (0%) | 0/37 (0%) |
| Event | Subcutaneous Tissue Release - 3 Years | Subcutaneous Tissue Release - Years 4-5 |
|---|---|---|
| ColdInfections and infestations | 2/55 | 0/37 |
| DiarrheaGastrointestinal disorders | 2/55 | 0/37 |
| HypercholesterolemiaMetabolism and nutrition disorders | 2/55 | — |
| Age, Continuous(Years) | Subcutaneous Tissue Release |
|---|---|
| Mean | 40.7 ± 9.1 |
| Sex: Female, Male(Participants) | Subcutaneous Tissue Release |
|---|---|
| Female | 55 |
| Male | 0 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Aug 2012, a primary completion of Sep 2013 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.